S&P 500 5,235.18 +1.02%EUR/USD 1.0840 +0.21%GBP/USD 1.2710 +0.14%USD/JPY 149.50 −0.18%BRENT $82.40 −0.81%BTC $67,800 −0.21%GOLD $2,341 +0.55%NASDAQ 16,420.55 +0.74%S&P 500 5,235.18 +1.02%EUR/USD 1.0840 +0.21%GBP/USD 1.2710 +0.14%USD/JPY 149.50 −0.18%BRENT $82.40 −0.81%BTC $67,800 −0.21%GOLD $2,341 +0.55%NASDAQ 16,420.55 +0.74%
A daily business newspaper · Founded in 2026

Money Talk

Finance and markets: business, quotes, gold, energy and releases.

Honeywell Aerospace Investors Face November Deadline in Securities Suit

Investors who purchased Honeywell Aerospace, Inc. securities between June 29 and September 1, 2026, have until November 23 to seek status as lead plaintiff in a pending class action lawsuit. The case, filed in the District of Arizona, alleges the company misled shareholders regarding supplier constraints and federal investigations.

Honeywell Aerospace Investors Face November Deadline in Securities Suit
Photo: Bio & News

The litigation, Green v. Honeywell Aerospace, Inc. (No. 26-cv-06779), centers on claims that the firm failed to disclose significant vulnerabilities in its supply chain. According to the complaint, a small group of suppliers exerted a disproportionate impact on sales, and those entities were struggling with material constraints. Furthermore, the suit alleges the company omitted information regarding an investigation into potential violations of the False Claims Act related to government cybersecurity requirements.

Kahn Swick & Foti, LLC, the firm representing the class, asserts these undisclosed factors rendered the company’s public statements concerning its business prospects materially misleading. Investors who suffered losses during the specified period are eligible to participate in the recovery process. While the deadline to request appointment as a lead plaintiff is November 23, 2026, participation in a potential settlement does not strictly require serving in that lead role.

Share article
TelegramXFacebook

When reusing this material a link to Money Talk is required.

Comments (0)

Leave a comment

No comments yet. Be the first!